Cecilia Guzman

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

G. Demetri, A. Huvos, R. Maki, 2003, Cancer.

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

G. Demetri, R. Maki, D. Ryan, 2002, Cancer Chemotherapy and Pharmacology.

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

J. Manola, G. Demetri, R. Maki, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

J. Manola, G. Demetri, R. Maki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule

J. Blay, G. Demetri, A. Cesne, 2001 .

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.

J. Bueren, J. Jimeno, G. Faircloth, 2002, European journal of cancer.